Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.
We designed a phase 1 study using dendritic cells (DCs) pulsed with a mixture of three types of Wilms' tumor 1 (WT1) peptides, including MHC class I/II restricted epitopes (DC/WT1-I/II). Our recent work reveals that the combination of DC/WT1-I/II and chemotherapy induced long-term WT1-specific CD4+and CD8+T cell responses.
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine ; Tokyo, Japan ; Institute of Clinical Medicine and Research; The Jikei University School of Medicine ; Tokyo, Japan ; Department of Oncology; The Jikei University School of Medicine ; Tokyo, Japan.
Shigeo
S
Koido
Department of Oncology; The Jikei University School of Medicine ; Tokyo, Japan.
Sadamu
S
Homma
Department of Advanced Immunotherapeutics; Kitasato University School of Pharmacy ; Tokyo, Japan.
Masato
M
Okamoto
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine ; Tokyo, Japan.
Kazuki
K
Takakura
Department of Medicine; Boston University School of Medicine ; Boston, MA USA.
Jianlin
J
Gong
Department of Functional Diagnostic Science; Graduate School of Medicine; Osaka University ; Osaka, Japan.
Haruo
H
Sugiyama
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine ; Tokyo, Japan.
Toshifumi
T
Ohkusa
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine ; Tokyo, Japan.
Hisao
H
Tajiri
MHC class II; WT1; dendritic cell; helper T cell